Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has provided an announcement.
CR Double-Crane, a subsidiary of China Resources Pharmaceutical Group, reported its unaudited financial results for the nine months ending September 30, 2025. The company experienced a slight decline in revenue and net profit compared to the previous year, with revenue at RMB 8.28 billion and net profit at RMB 1.39 billion. Despite a decrease in cash and cash equivalents, the company saw an increase in total assets and owner’s equity, indicating a stable financial position. Shareholders and investors are advised to exercise caution as the financials are unaudited and may require adjustments.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products. It holds a significant stake in CR Double-Crane, a company listed on the Shanghai Stock Exchange, which is involved in the pharmaceutical sector in China.
Average Trading Volume: 16,744,630
Technical Sentiment Signal: Sell
Current Market Cap: HK$30.6B
Learn more about 3320 stock on TipRanks’ Stock Analysis page.